Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Longboard Pharmaceuticals, Inc. (LBPH)

Sector - Healthcare

Price chart

-37.81%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. They were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Their small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Their pipeline includes: LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist, that they are advancing in a multiple-ascending dose (MAD) portion of a Phase 1 clinical trial and expect to initiate a Phase 1b/2a clinical trial for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others, in the first quarter of 2022; LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist in investigational new drug application (IND)-enabling studies for neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS); and LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases.
Industry
Pharmaceuticals
CEO CFO
Kevin R. Lind Brandi L. Roberts
Employees Founded
6 2020

Contacts

Address: 6154 Nancy Ridge Drive San Diego, California 92121

Telephone: (619) 592-9775

Web page: http://www.longboardpharma.com

IPO information

First Trade Date 3/12/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5
Shares Revised (MM) 5
Expected offer amount (MM) $75
Realized offer amount(MM) $80

Financial Data (last reporting year)

Market Cap (MM) $253.8
Revenues (MM) $0
Net Income (Loss) (MM) $-14.4

Voting

What do you think will happen with the LBPH share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Citigroup

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Citigroup/ Evercore ISI/ Guggenheim Securities/ Cantor
CO-Managers
-

Sector: Healthcare

Tweets about $LBPH

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats